PRA Health Sciences (NASDAQ:PRAH) had its price objective increased by Jefferies Financial Group from $115.00 to $120.00 in a research report released on Friday, The Fly reports. The brokerage currently has a buy rating on the medical research company’s stock.

A number of other equities analysts have also recently issued reports on the company. Svb Leerink reaffirmed a market perform rating on shares of PRA Health Sciences in a report on Tuesday, July 2nd. BidaskClub upgraded PRA Health Sciences from a hold rating to a buy rating in a report on Wednesday, July 24th. Barclays upped their price objective on PRA Health Sciences from $115.00 to $118.00 and gave the company an overweight rating in a research note on Wednesday, September 4th. Finally, Leerink Swann initiated coverage on PRA Health Sciences in a research note on Tuesday, July 2nd. They issued a market perform rating and a $105.00 price objective for the company. Eight analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $115.00.

Shares of PRA Health Sciences stock opened at $100.04 on Friday. PRA Health Sciences has a fifty-two week low of $82.12 and a fifty-two week high of $121.98. The company has a debt-to-equity ratio of 1.11, a current ratio of 0.99 and a quick ratio of 0.99. The firm has a market capitalization of $6.81 billion, a P/E ratio of 25.46, a P/E/G ratio of 1.39 and a beta of 1.13. The company’s 50 day moving average price is $98.43 and its two-hundred day moving average price is $98.71.

PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Wednesday, July 31st. The medical research company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.11. PRA Health Sciences had a net margin of 5.39% and a return on equity of 26.64%. The firm had revenue of $763.31 million for the quarter, compared to analysts’ expectations of $764.95 million. During the same quarter in the previous year, the firm posted $1.00 earnings per share. The company’s revenue was up 5.6% on a year-over-year basis. On average, analysts expect that PRA Health Sciences will post 4.63 earnings per share for the current year.

A number of large investors have recently made changes to their positions in PRAH. Municipal Employees Retirement System of Michigan increased its stake in shares of PRA Health Sciences by 1.0% in the second quarter. Municipal Employees Retirement System of Michigan now owns 10,900 shares of the medical research company’s stock valued at $1,081,000 after buying an additional 110 shares during the period. Glen Harbor Capital Management LLC raised its position in shares of PRA Health Sciences by 1.0% during the second quarter. Glen Harbor Capital Management LLC now owns 11,508 shares of the medical research company’s stock worth $1,141,000 after acquiring an additional 112 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of PRA Health Sciences by 1.3% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,390 shares of the medical research company’s stock worth $1,146,000 after acquiring an additional 129 shares during the period. Elkfork Partners LLC lifted its stake in shares of PRA Health Sciences by 1.0% in the second quarter. Elkfork Partners LLC now owns 13,974 shares of the medical research company’s stock worth $1,385,000 after acquiring an additional 136 shares during the period. Finally, Crossmark Global Holdings Inc. lifted its stake in shares of PRA Health Sciences by 1.6% in the first quarter. Crossmark Global Holdings Inc. now owns 8,840 shares of the medical research company’s stock worth $975,000 after acquiring an additional 140 shares during the period. 99.64% of the stock is owned by institutional investors and hedge funds.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

See Also: What are some reasons analysts would give stocks a buy rating?

The Fly

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.